NL-OMON28133
Recruiting
Not Applicable
Intranasal LMWH against COVID-19
ConditionsCOVID-19
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- ZonMW
- Enrollment
- 34
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
none yet
Investigators
Eligibility Criteria
Inclusion Criteria
- •In order to be eligible for participation, a participant must:
- •\- be able to provide written informed consent (Verbal informed consent or deferred informed concent will be used for the initial screening visit, where written informed consent will be obtained).
- •\- be physically healthy (as defined by not suffering from any illness or disease obstructing general daily functioning)
- •\- be aged between 18 – 65 years
- •\- be sufficiently well versed in the Dutch language, subject to the opinion of the Investigator
Exclusion Criteria
- •If any of the following apply to someone wishing to participate, he/she is rendered ineligible for participation, a participant:
- •\- is unlikely to comply with study procedures, as deemed by the recruiting research doctor/nurse
- •\- has mental disorders that in the view of the investigator would interfere with adherence to study procedures or might impair a decision to participate in the study
- •\- has a known allergy or intolerance to LWWH or heparine\-related products, as well as a medical history of heparine inducted thrombocytopenia (HIT).
- •\- has any relevant clinical medical condition that is in the opinion of the investigator to make a volunteer unsuitable for participation in the study (under which underlying haematological disorders or bleeding disorder.
- •\- has (anamnestic) evidence of a respiratory infection in the 4 weeks prior to enrolment.
- •\- has a tympanic temperature exceeding 38,5 degrees Celsius during the screening and clinical visits.
- •\- has frequent nosebleeds (\>1/ month).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
High-Flow Nasal Cannula for severe COVID-19, a multicentre prospective cohort study<p>COVID-19</p>NL-OMON19993o sponsors600
Completed
Phase 2
COVID-19: Nasal spray Treatment with the well-established antiallergic Azelastine for prevention of SARS-CoV-2 INfections (CONTAIN)COVID-19 prophylaxisDRKS00031059RSAPHARM Arzneimittel GmbH450
Not yet recruiting
Phase 2
se of Steroid inhalers in COVID.CTRI/2021/05/033817YOU BREATHE WE CARE
Completed
Not Applicable
Impact of high flow oxygen therapy on outcomes of COVID-19 patientsCTRI/2020/10/028634Rajendra Institute of Medical Sciences114
Not yet recruiting
Not Applicable
High Flow Nasal Oxygen Therapy in COVID-19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/12/030015All India Institute of Medical Sciences Jodhpur